# US 8,278,423 B2 · Monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,423 B2
- Document ID: US8278423B2
- Status: Granted
- Kind: B2
- Application number: 12/513,248
- Filed: 2007-10-31
- Published: 2010-06-03
- Granted: 2012-10-02
- Earliest claimed: 2006-11-02
- Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Inventors: Isabelle Teulon; André Pelegrin
- Web page: https://patentgrep.com/patent/US8278423B2

## CPC

- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.

## Claims

### Claim 1

A monoclonal antibody having specificity for human Anti-Müllerian Hormone type II receptor (AMHR-II) which comprises:
(a) a heavy chain which comprises SEQ ID NO: 2 for CDR-1, SEQ ID NO: 3 for CDR-2 and SEQ ID NO: 4 for CDR-3; and
(b) a light chain which comprises SEQ ID NO: 6 for CDR-1, SEQ ID NO: 7 for CDR-2 and SEQ ID NO: 8 for CDR-3.

### Claim 2 (depends on 1)

The monoclonal antibody, according to claim 1, which comprises:
(a) a variable domain of heavy chain having the amino acid sequence set forth as SEQ ID NO: 1; and
(b) a variable domain of light chain having the amino acid sequence set forth as SEQ ID NO: 5.

### Claim 3 (depends on 1)

The monoclonal antibody according to claim 1, wherein said antibody is a murine antibody.

### Claim 4 (depends on 3)

The monoclonal antibody according to claim 3, wherein said antibody is obtainable from hybridoma accessible under CNCM deposit number I-3673.

### Claim 5 (depends on 1)

The monoclonal antibody according to claim 1, wherein said antibody is a mouse/human chimeric antibody.

### Claim 6 (depends on 1)

The monoclonal antibody according to claim 1, wherein said antibody is an humanized antibody.

### Claim 7

A fragment of a monoclonal antibody, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-11) and comprises:
(a) a heavy chain which comprises SEQ ID NO: 2 for CDR-1, SEQ ID NO: 3 for CDR-2 and SEQ ID NO: 4 for CDR-3; and
(b) a light chain which comprises SEQ ID NO: 6 for CDR-1, SEQ ID No: 7 for CDR-2 and SEQ ID NO: 8 for CDR-3,
wherein the fragment is selected in the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies.

### Claim 8

A pharmaceutical composition comprising an antibody, and/or a fragment of an antibody, together with a pharmaceutically acceptable carrier; wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
(a) a heavy chain which comprises SEQ ID NO: 2 for CDR-1, SEQ ID NO: 3 for CDR-2 and SEQ ID NO: 4 for CDR-3; and
(b) a light chain which comprises SEQ ID NO: 6 for CDR-1, SEQ ID NO: 7 for CDR-2 and SEQ ID NO: 8 for CDR-3;
and wherein the fragment is selected in the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies.

### Claim 9

An immunoconjugate comprising an antibody, or a fragment of an antibody, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (MHR-II) and comprises:
(a) a heavy chain which comprises SEQ ID NO: 2 for CDR-1, SEQ ID NO: 3 for CDR-2 and SEQ ID NO: 4 for CDR-3; and
(b) a light chain which comprises SEQ ID NO: 6 for CDR-1, SEQ ID NO: 7 for CDR-2 and SEQ ID NO: 8 for CDR-3, conjugated to an anti-cancer agent;
and wherein the fragment is selected in the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies.

### Claim 10 (depends on 9)

The immunoconjugate according to claim 9 wherein said anti-cancer agent is a cytotoxic agent or a growth inhibitory agent.

### Claim 11 (depends on 1, 7)

The antibody according to claim 1, or a fragment of a monoclonal antibody according to claim 7, which is labelled with a detectable molecule or substance.

### Claim 12

A method for treating an ovarian cancer comprising administering a subject in need thereof with a therapeutically effective amount of an antibody, or a fragment of an antibody, or an immunoconjugate comprising an antibody or a fragment of an antibody conjugated to an anticancer agent, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
(a) a heavy chain which comprises SEQ ID NO: 2 for CDR-1, SEQ ID NO: 3 for CDR-2 and SEQ ID NO: 4 for CDR-3; and
(b) a light chain which comprises SEQ ID NO: 6 for CDR-1, SEQ ID NO: 7 for CDR-2 and SEQ ID NO: 8 for CDR-3;
and wherein the fragment is selected in the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies.

### Claim 13

A method of diagnosing and/or monitoring an ovarian cancer in a subject, comprising the steps of:
(i) contacting a biological sample of a subject likely to suffer from an ovarian cancer with an antibody, or a fragment of an antibody, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
(a) a heavy chain which comprises SEQ ID NO: 2 for CDR-1, SEQ ID NO: 3 for CDR-2 and SEQ ID NO: 4 for CDR-3; and
(b) a light chain which comprises SEQ ID NO: 6 for CDR-1, SEQ ID NO: 7 for CDR-2 and SEQ ID NO: 8 for CDR-3,
and wherein the fragment is selected in the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies,
in conditions sufficient for the antibody or the fragment of antibody to form complexes with cells of the biological sample that express AMHR-II and
(ii) detecting and/or quantifying said complexes;
whereby the detection of said complexes is indicative of an ovarian cancer.
